NeoMET Study in Neoadjuvant Treatment of Breast Cancer
- Conditions
- pCR RateBCT RateSafety
- Interventions
- Registration Number
- NCT01929811
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Brief Summary
To evaluate docetaxel, epirubicin and cyclophosphomide (TEC) with TEC plus metformin in neoadjuvant treatment of breast cancer patients. The aim is to evaluate whether metformin can increase the pCR rate combination with TEC regimen in neoadjuvant setting.
- Detailed Description
Neoadjuvant therapy is the standard treatment for locally advanced breast cancer and has adopted in early breast cancer treatment. A meta-analysis showed no difference between neoadjuvant therapy and adjuvant therapy in terms of survival and overall disease progression. Therefore, neoadjuvant treatment can be offered as a standard treatment and as an alternative to adjuvant treatment to all patients who are expected to be candidates for adjuvant systemic chemotherapy. Patients achieved pCR after treatment have superior outcome.
The taxanes were introduced into clinical practice in the early 1990s, and recent meta-analysis showed that compared with anthracycline-containing chemotherapy, taxanes-containing regimens significantly reduced the annual breast cancer recurrences and deaths. Right now, TAC regimen has widely accepted as adjuvant or neoadjuvant chemotherapy regimens in breast cancer treatment.
Metformin, an inexpensive oral agent commonly used to treat type 2 diabetes, has been garnering increasing attention as a potential anti-cancer agent. In neoadjuvant treatment of breast cancer, a retrospective clinical study from MDACC reported a significantly increased pCR rates to standard neoadjuvant chemotherapy in diabetic breast cancer patients who were receiving metformin (24% pCR) compared to diabetics not receiving metformin (8% pCR), with intermediate rates in non-diabetics who did not receive metformin (16% pCR), indicating metformin may increase pCR rate with neoadjuvant chemotherapy.
Base on these data, we initiate a prospective study to evaluate docetaxel, epirubicin and cyclophosphomide (TEC) with TEC plus metformin in neoadjuvant treatment of breast cancer patients. Our aim is to evaluate whether metformin can increase the pCR rate combination with TEC regimen in neoadjuvant setting.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- 92
- women aged ≥18 years and < 70 years with life expectancy > 12 months
- Measurable disease in breast or axillary lymph node, histologically confirmed invasive breast cancer by core needle biopsy, T≥2cm or stage IIb or stage III according AJCC classification, fine-needle aspiration is encouraged to every patient with metastasis suspicious nodes;
- Biopsy specimens are available for ER, PgR, Her2 and proliferation biomarker detection;
- Adequate bone marrow function: Neutrophil ≥ 1.5*109/L; Hb ≥ 100g/L; PLT ≥ 80*109/L;
- Adequate liver and renal function:
- Serum AST ≤ 90U/L
- Bilirubin ≤ upper limit of normal (UNL) range
- Serum creatinine ≤110 umol/L，calculated creatinine clearance should be ≥ 60 mL/min;
- BUN ≤ 7.1mmol/L;
- Has ECOG Performance Score 0-1;
- BMI ≥ 25kg/m2 or hyperglycemia or hyperlipemia or hypertension;
- Willing to take biopsy before neoadjuvant chemotherapy and patients must be accessible for treatment and follow-up;
- Women with potential child-bearing must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable method of birth control to avoid pregnancy for the duration of the study;
- Written informed consent according to the local ethics committee requirements.
- Prior systemic or loco-regional treatment of breast cancer, including chemotherapy;
- Metastatic breast cancer;
- With a history of malignant tumor except uterine cervix cancer in situ or skin basal cell carcinoma;
- Patients with medical conditions that indicate intolerant to neoadjuvant therapy and related treatment, including uncontrolled pulmonary disease, severe infection, active peptic ulcer, coagulation disorder, connective tissue disease or myelo-suppressive disease;
- Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is known to be HIV positive;
- Contraindication for using dexamethasone, chemotherapy agents or metformin;
- History of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction; poorly controlled hypertension (systolic BP >180mmHg or diastolic BP >100mmHg);
- Has peripheral neuropathy ≥ grade 1;
- Patient is pregnant or breast feeding (not willing to stop breast feeding);
- Not willing to take core needle biopsy or patients with psychiatric disorder or other diseases leading to incompliance to the therapy
- Known severe hypersensitivity to any drugs in this study;
- Treatment with any investigational drugs within 30 days before the beginning of study treatment.
- History of lactic or other metabolic acidosis
- Consumption of > 3 alcoholic beverages per day (on average)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Metformin arm cyclophosphomide Docetaxel: 75mg/m2, d1, q3w\*6 Epirubicin: 75mg/m2, d1, q3w\*6 Cyclophosphamide: 500mg/m2, d1, q3w\*6 Metformin: 500mg tid, orally (500mg daily in first cycle) TEC cyclophosphomide Docetaxel: 75mg/m2, d1, q3w\*6 Epirubicin: 75mg/m2, d1, q3w\*6 Cyclophosphamide: 500mg/m2, d1, q3w\*6 Metformin arm Metformin Docetaxel: 75mg/m2, d1, q3w\*6 Epirubicin: 75mg/m2, d1, q3w\*6 Cyclophosphamide: 500mg/m2, d1, q3w\*6 Metformin: 500mg tid, orally (500mg daily in first cycle) Metformin arm Epirubicin Docetaxel: 75mg/m2, d1, q3w\*6 Epirubicin: 75mg/m2, d1, q3w\*6 Cyclophosphamide: 500mg/m2, d1, q3w\*6 Metformin: 500mg tid, orally (500mg daily in first cycle) Metformin arm Docetaxel Docetaxel: 75mg/m2, d1, q3w\*6 Epirubicin: 75mg/m2, d1, q3w\*6 Cyclophosphamide: 500mg/m2, d1, q3w\*6 Metformin: 500mg tid, orally (500mg daily in first cycle) TEC Docetaxel Docetaxel: 75mg/m2, d1, q3w\*6 Epirubicin: 75mg/m2, d1, q3w\*6 Cyclophosphamide: 500mg/m2, d1, q3w\*6 TEC Epirubicin Docetaxel: 75mg/m2, d1, q3w\*6 Epirubicin: 75mg/m2, d1, q3w\*6 Cyclophosphamide: 500mg/m2, d1, q3w\*6
- Primary Outcome Measures
Name Time Method pathologic complete response rate 5 months To compare pathologic complete response (pCR) rate to neoadjuvant chemotherapy between Docetaxel, Epirubicin and Cyclophosphamide (TEC) arm and TEC plus Metformin arm in breast cancer.
Definition of pCR is no invasive tumor in primary breast and axillary lymph node.
- Secondary Outcome Measures
Name Time Method safety profile up to 4.5 months To compare the tolerability and side effects of neoadjuvant chemotherapy between Docetaxel, Epirubicin and Cyclophosphamide (TEC) arm and TEC plus Metformin arm in breast cancer treatment.
Clinical response rate up to 4.5 months To compare the clinical response rate between Docetaxel, Epirubicin and Cyclophosphamide (TEC) arm and TEC plus Metformin arm in breast cancer neoadjuvant treatment.
breast conservation therapy (BCT) rate 5 months
Trial Locations
- Locations (2)
Linyi People's Hospital
🇨🇳Linyi, Shandong, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
🇨🇳Shanghai, Shanghai, China